Article Information
History
- March 26, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- María Íñiguez1,
- Patricia Pérez-Matute1,
- Pablo Villoslada-Blanco1,
- Emma Recio-Fernandez1,
- Diana Ezquerro-Pérez2,
- Jorge Alba2,
- M. Lourdes Ferreira-Laso3 and
- José A. Oteo4,*
- 1Infectious Diseases, Microbiota and Metabolism Unit, Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain
- 2Infectious Diseases Department. Hospital Universitario San Pedro, Logroño, Spain
- 3Department of Anesthesiology and Postoperative Care, Hospital Universitario San Pedro, Logroño, Spain
- 4Infectious Diseases, Microbiota and Metabolism Unit, Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain; Infectious Diseases Department, Hospital Universitario San Pedro, Logroño, Spain
- ↵*Corresponding author: José Antonio Oteo, PhD, MD E-mail: jaoteo{at}riojasalud.es
Posted March 26, 2021.
ACE gene variants rise the risk of severe COVID-19 in patients with hypertension, dyslipidemia or diabetes. A pilot study
